Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067509 | 0.87 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL4785666 | 0.85 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL3312180 | 0.84 | HCRTR1 (0.45) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL3059998 | 0.83 | HCRTR1 (0.54) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL2056960 | 0.82 | HCRTR1 (0.47) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL1398848 | 0.82 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL4785253 | 0.77 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL2635804 | 0.76 | HCRTR1 (0.48) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL1398768 | 0.75 | HCRTR1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL3312174 | 0.74 | HCRTR2 (0.46) | HCRTR1HCRTR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885ALDH1A1 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.